Immutep to Present New Phase IIb Data in PD-L1 Negative Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep Limited, a clinical-stage biotechnology company known for its work in LAG-3 immunotherapies for cancer and autoimmune diseases, has announced new data from its TACTI-003 Phase IIb trial. This trial focuses on first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma patients who have negative PD-L1 expression, specifically those with a combined positive score (CPS) of less than 1. The findings will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2024, which is scheduled to take place from 11-13 December in Geneva, Switzerland.

The presentation, titled "TACTI-003 Cohort B: Eftilagimod Alpha (Soluble LAG-3) and Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck Squamous Cell Carcinoma with CPS <1," will be delivered by Dr. Martin Forster from the University College London (UCL) Cancer Institute and UCL Hospital NHS Foundation. The presentation will occur on Thursday, 12 December 2024, from 12:30 to 13:30 CET, under presentation number 152P.

Abstracts of the presentation will be available on the ESMO I-O website starting 5 December 2024, at 00:05 CET. In addition to the abstract, a poster containing new data will be accessible in the Posters & Publications section of Immutep’s website subsequent to the presentation on 12 December 2024.

Immutep is recognized for its pioneering work in Lymphocyte Activation Gene-3 (LAG-3) immunotherapy. The company’s diverse product portfolio is designed to either stimulate or suppress the immune response, making it a significant player in the development of treatments for cancer and autoimmune diseases. The organization is dedicated to using its expertise to create innovative treatments for patients and to enhance value for its shareholders.
 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!